Nasdaq cprx.

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for ...The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has done very well over the last month, posting an excellent gain of 27%. Looking back a bit further, it's encouraging to see the stock ...Find the latest Institutional Holdings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.

Catalyst Pharmaceuticals ( NASDAQ: CPRX) is a commercial-stage biopharmaceutical entity dedicated to in-licensing, developing, and marketing novel treatments for rare and challenging diseases ...

CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …

(NASDAQ: CPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.13%. What is CPRX's Price Target? According to 3 Wall Street analyst s that have issued a 1 year CPRX price target, the average CPRX price target is $25.00 , with the highest CPRX stock price forecast at $27.00 and the lowest CPRX …09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ...Apr 7, 2023 · The S&P 500 is up 6% in 2023, and the tech-heavy Nasdaq composite shows a 14% gain. ... (NASDAQ:CPRX) is at the forefront of developing medications to treat the aging population. Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 70% over the last three months. Given the company's impressive performance, we ...The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. …

CPRX Stock 12 Months Forecast. $23.30. (81.32% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $23.30 with a high forecast of $27.00 and a low forecast of $15.50. The average price target represents a 81.32% change from the last price of $12.85.

Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second …

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the …CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours... CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours... Apr 7, 2023 · The S&P 500 is up 6% in 2023, and the tech-heavy Nasdaq composite shows a 14% gain. ... (NASDAQ:CPRX) is at the forefront of developing medications to treat the aging population. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) dropped 7.5% during mid-day trading on Friday . The company traded as low as $12.43 and last traded at $12.43. Approximately ...

The latest price target for Catalyst Pharmaceuticals ( NASDAQ: CPRX) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 27.00 expecting CPRX to ...(Nasdaq: CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common ...Catalyst Pharmaceuticals’ (NASDAQ:CPRX) top drug is Firdapse, which is used to treat adults with Lambert-Eaton Myasthenic Syndrome, a rare condition that affects signals sent from nerves to ...The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ...Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, Inc ...

Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.

Anyone interested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should probably be aware that the Chief Commercial Officer, Jeffrey Del Carmen, recently divested US$199k worth of shares in the ...Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Securities registered pursuant to Section 12(g) of the Act.: None Indicate by check mark if registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒Feb 28, 2023 · Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ... Catalyst Pharmaceutical (CPRX) closed at $15.25 in the latest trading session, marking a -1.74% move from the prior day. This move was narrower than the S&P 500's daily loss of 2%. Meanwhile, the ...Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business?We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, …CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") CPRX today announced the appointment of Michael W. Kalb as its Executive Vice ...Find the latest historical data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Oct 16, 2023 · Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine). CPRX's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend.com: The #1 Source For Dividend Investing. Home Guide ... CPRX: NASDAQ (Stock) CATALYST PHARMACEUTICALS, INC. Payout Change None Price as of: NOV 24, 08:00 AM EST $14.06 +0.2 +0% Dividend (Fwd) $0.00

10 hours ago · CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...

Shares of Catalyst Pharmaceutical (CPRX) have gained 8.4% over the past four weeks to close the last trading session at $16.53, but there could still be a solid upside left in the stock if short ...

ADVISORY, Aug. 18, 2015 (GLOBE NEWSWIRE) --What: Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with ...09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ...Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13 % change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.54B.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in …Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call Transcript. Published on November 10, 2023 at 11:20 am by Insider Monkey Transcripts in News, Transcripts. Charles Duncan: And ...To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve.Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine).Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. View live Catalyst Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, CPRX financials and market news.Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ...Shareholders of Catalyst Pharmaceuticals ( CPRX -1.13%) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries ( TEVA -1.12%), was planning to ...

CPRX: NASDAQ (Stock) CATALYST PHARMACEUTICALS, INC. DEC 01, 11:00 AM EST $14.82 +0% Dividend (Fwd) $0.00 Yield (Fwd) Annualized forward dividend yield. Multiplies the ...TipRanks | Stock Market Research, News and Analyst Forecasts ... Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.Instagram:https://instagram. gold royalty stockbest health insurance in oklahomahow to use etrade to buy stocksblnk stock forecast Based in Coral Gables, Florida, Catalyst Pharmaceuticals (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people ...Aug 29, 2021 · NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ... wilde wealth managementambetter north carolina reviews Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...Catalyst Pharmaceutical (CPRX) closed at $15.25 in the latest trading session, marking a -1.74% move from the prior day. This move was narrower than the S&P 500's daily loss of 2%. stock market history chart by month Catalyst Pharmaceuticals, inc (CPRX) Q2 2021 Earnings Call Transcript CPRX earnings call for the period ending June 30, 2021. Motley Fool Transcribers | Aug 10, 2021Catalyst is undervalued at its current valuation with a P/E GAAP (TTM) of 8.13, when compared against the sector median of 36.43. Catalyst Pharmaceuticals ( NASDAQ: CPRX) is a small cap ...Oct 5, 2022 · Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 70% over the last three months. Given the company's impressive performance, we ...